The long-term objective of our research plan is to reduce the disproportionate effects of breast cancer on African American women, especially those belonging to the Triple Negative subtype (i.e., ER-, PR- and Her2-). A guiding principle of our methodology is biochemical differences exist between TN breast cancers of African American and European American origin and that these differences can explain, in part, breast cancer health disparity. In this application, we propose characterization one such alteration in Kynurenine metabolism. High levels of the metabolites Kynurenine and Tryptophan were found in a subset of TN breast cancers, predominantly African American, with poor clinical outcome. These patients also showed higher expression of the RAS oncogene. Based on these we hypothesize that higher levels of the metabolite Kynurenine in association with RAS signaling, could lead to aggressive tumors within the African American women, having TN breast cancer. Further, we propose that characterization of the role of Kynurenine metabolism in TN African American breast cancer could help address the issue of racial disparity in breast cancer clinical outcomes.

Public Health Relevance

Disparity exists between African-American and European-American women, in the clinical outcome of Triple Negative Breast Cancer. At present, the biological mechanisms, underlying the disparity are not well defined. The information gleaned from this proposal could rapidly revolutionize current prognostic and therapeutic approaches by revealing the biological underpinnings associated with Triple Negative Breast Cancer Disparity.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Wallace, Tiffany A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Anatomy/Cell Biology
Schools of Medicine
United States
Zip Code
Mishra, Prachi; Tang, Wei; Putluri, Vasanta et al. (2018) ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming. J Clin Invest 128:323-340
Tian, Lin; Goldstein, Amit; Wang, Hai et al. (2017) Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544:250-254
Noonepalle, Satish K; Gu, Franklin; Lee, Eun-Joon et al. (2017) Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers. Cancer Immunol Res 5:330-344
von Rundstedt, Friedrich-Carl; Rajapakshe, Kimal; Ma, Jing et al. (2016) Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. J Urol 195:1911-9
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Arnold, James M; Choi, William T; Sreekumar, Arun et al. (2015) Analytical strategies for studying stem cell metabolism. Front Biol (Beijing) 10:141-153
Bhowmik, Salil Kumar; Ramirez-Peña, Esmeralda; Arnold, James Michael et al. (2015) EMT-induced metabolite signature identifies poor clinical outcome. Oncotarget 6:42651-60
Lloyd, Stacy M; Arnold, James; Sreekumar, Arun (2015) Metabolomic profiling of hormone-dependent cancers: a bird's eye view. Trends Endocrinol Metab 26:477-85
Jin, Feng; Bhowmik, Salil Kumar; Putluri, Vasanta et al. (2015) A Novel [(15)N] Glutamine Flux using LC-MS/MS-SRM for Determination of Nucleosides and Nucleobases. J Anal Bioanal Tech 6: